During a new study, an oral prodrug has been developed by researchers that deliver carbon monoxide to protect against acute kidney injury. The study published in Chemical Science was conducted by a team of scientists led by Binghe Wang, Regents’ Professor of Chemistry at Georgia State University. Although carbon monoxide (CO) gas is toxic in large doses, scientists have discovered it can have beneficial effects by reducing inflammation and protecting cells against injury. Previous studies have demonstrated the protective effects of CO against injury in the kidneys, lungs, gastrointestinal tract and liver, among other organs.
For the past five years, Wang and his collaborators have worked to design a safe way to deliver CO to human patients via prodrugs — inactive compounds that must undergo a chemical process in the body before releasing the active pharmacological agent. Wang’s team developed prodrugs that allow for oral administration of CO using two common artificial sweeteners — saccharine (an ingredient in Sweet’N Low) and acesulfame (an ingredient in Splenda) — as “carrier” molecules. They designed the molecules to release CO in the process of decomposition, which is triggered by exposure to water. These are the first examples of orally active, organic CO prodrugs using a benign carrier that is approved by the Food & Drug Administration with a demonstrated safety profile.
“It’s difficult to deliver a gas, much less a poisonous gas, as a therapeutic to patients, and this work represents a pivotal step forward in developing alternative delivery forms,” said Wang, senior author of the paper and a Georgia Research Alliance Eminent Scholar. “We wanted to work with a carrier that has a very well-characterized safety profile, which confers a higher degree of certainty that it will be safe to use in a pill for human consumption.”
Of the two prodrugs, the scientists tested one, CO-306, for pharmacological efficacy against acute kidney damage. The researchers administered CO-306, which uses saccharine as a carrier molecule, to mice and found it reduced biomarkers associated with kidney injury, indicating it could be developed into a viable therapy.
The mouse model mimicked the mechanisms of kidney tissue damage that occur in patients with extensive muscle damage, sickle cell disease, a common type of malaria, cardiopulmonary bypass surgery and severe sepsis. Wang and his collaborators at Georgia State’s Center for Diagnostics and Therapeutics, Vanderbilt University, Harvard Medical School and the University of Mississippi plan to conduct extensive animal model studies and safety assessments on CO-306 before progressing to human clinical studies. They also plan to test CO-306 for efficacy against other types of organ injuries.
Wang says CO-based therapies particularly hold promise as a method of reducing the likelihood of organ damage during transplantation and improving outcomes for transplant patients.
